Syngene InternationalNSE:SYNGENE +1.23%81 Net Margin % is 14.27% as of Mar. 2026, which is 19% below its 10-year median of 17.56. GuruFocus rates NSE:SYNGENE with a GF Score™ of 81/100 and a GF Value™ of ₹788.70 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Syngene International ranks better than 73.4% on this metric.
The historical rank and industry rank for Syngene International's Net Margin % or its related term are showing as below:
NSE:SYNGENE'
s Net Margin % Range Over the Past 10 Years
Min: 8.47 Med: 17.56 Max: 24.57
Current: 8.47
NSE:SYNGENE's Net Margin % is ranked better than 73.4% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.43
vs NSE:SYNGENE: 8.47
Syngene International (NSE:SYNGENE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Syngene International Net Margin % Related Terms
Syngene International Net Margin % Historical Data
* Premium members only.
The historical data trend for Syngene International's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SYNGENE vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Syngene International's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's Net Margin % distribution charts can be found below:
* The bar in red indicates where Syngene International's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngene International (NSE:SYNGENE) has a Net Margin % of 14.27% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Syngene International and its competitors. This is 19% below median its historical median of 17.56. Over the past decade, Syngene International's Net Margin % has ranged from 8.47 to 24.57. According to the industry distribution chart, Syngene International ranks #54 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 26.6%.
Is Syngene International's Net Margin % too high?
Syngene International's current Net Margin % of 14.27% is 19% below median its 10-year median of 17.56. Over the past 10 years, this metric has ranged from a low of 8.47 to a high of 24.57. Based on the distribution chart, Syngene International ranks #54 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Syngene International has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #54 out of 203 companies for Net Margin %. This puts Syngene International in the upper half of its industry. Historically, Syngene International's own Net Margin % has ranged from 8.47 to 24.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Syngene International and its competitors. Syngene International's current Net Margin % is 14.27%, which is 19% below median its own 10-year median of 17.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹788.70, compared to a current price of ₹439.50 — trading 44.3% below its estimated fair value. The current Net Margin % is 14.27%, which is 19% below median its 10-year median of 17.56. Syngene International's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Net Margin % is 14.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹439.50 is trading 44.3% below its estimated GF Value™ of ₹788.70.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
Net Margin %: 14.27% (19% below median its 10-year median of 17.56)
GF Value™: ₹788.70 vs. price of ₹439.50 (44.3% below fair value)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
81GF Score
Get the complete analysis for NSE:SYNGENE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
